Published in J Am Podiatr Med Assoc on November 01, 1995
The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol (2001) 3.92
Sterility of refrigerated injectable collagen syringes after injection of patient. J Am Acad Dermatol (1992) 2.05
Finasteride in the treatment of men with frontal male pattern hair loss. J Am Acad Dermatol (1999) 1.67
Duration of remission of psoriasis therapies. J Am Acad Dermatol (1999) 1.51
Pustular and erythrodermic psoriasis complicated by acute respiratory distress syndrome. Arch Dermatol (1997) 1.48
Proceedings of the Psoriasis Combination and Rotation Therapy Conference. Deer Valley, Utah, Oct. 7-9, 1994. J Am Acad Dermatol (1996) 1.45
New cutaneous manifestations of systemic diseases. Am Fam Physician (1995) 1.42
Effect of UV-B phototherapy on plasma HIV type 1 RNA viral level: a self-controlled prospective study. Arch Dermatol (1998) 1.40
A 500-kb region on chromosome 16p13.1 contains the pseudoxanthoma elasticum locus: high-resolution mapping and genomic structure. J Mol Med (Berl) (2000) 1.39
Methotrexate in psoriasis: consensus conference. J Am Acad Dermatol (1998) 1.39
Atopic dermatitis. Lancet (1998) 1.37
Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. Br J Dermatol (2013) 1.26
Cellular differentiation and expression of matrix genes in type 1 neurofibromatosis. Lab Invest (1988) 1.19
Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis? J Am Acad Dermatol (2000) 1.12
Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis. J Am Acad Dermatol (2000) 1.11
Metastatic Crohn's disease. J Am Acad Dermatol (1984) 1.07
Diagnosis of pseudoxanthoma elasticum by scar biopsy in patients without characteristic skin lesions. N Engl J Med (1987) 1.07
Induction of 8-oxo-7,8-dihydro-2'-deoxyguanosine by ultraviolet radiation in calf thymus DNA and HeLa cells. Photochem Photobiol (1997) 1.06
Altered expression of angiopoietins and Tie2 endothelium receptor in psoriasis. J Invest Dermatol (2001) 1.05
Pseudoxanthoma elasticum: significance of limited phenotypic expression in parents of affected offspring. J Am Acad Dermatol (2001) 1.05
Identification of possible reactive oxygen species involved in ultraviolet radiation-induced oxidative DNA damage. Free Radic Biol Med (1997) 1.00
Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies. Br J Dermatol (2011) 1.00
Benzo[a]pyrene enhances the formation of 8-hydroxy-2'-deoxyguanosine by ultraviolet A radiation in calf thymus DNA and human epidermoid carcinoma cells. Biochemistry (1998) 0.98
Anti-CD4 monoclonal antibody treatment of moderate to severe psoriasis vulgaris: results of a pilot, multicenter, multiple-dose, placebo-controlled study. J Am Acad Dermatol (2000) 0.97
Assessment and management of methotrexate hepatotoxicity in psoriasis patients: report from a consensus conference to evaluate current practice and identify key questions toward optimizing methotrexate use in the clinic. J Eur Acad Dermatol Venereol (2010) 0.97
DNA structural integrity and base composition affect ultraviolet light-induced oxidative DNA damage. Biochemistry (1998) 0.96
Collagen alterations in chronically sun-damaged human skin. Photochem Photobiol (1993) 0.95
Scavenging of hydrogen peroxide and inhibition of ultraviolet light-induced oxidative DNA damage by aqueous extracts from green and black teas. Free Radic Biol Med (1999) 0.95
The insulin-like growth factor 1 receptor is expressed by epithelial cells with proliferative potential in human epidermis and skin appendages: correlation of increased expression with epidermal hyperplasia. J Invest Dermatol (1996) 0.94
Calcification of elastic fibers in pseudoxanthoma elasticum. Mt Sinai J Med (1996) 0.93
Subcutaneous fat necrosis of the newborn with hypercalcemia. J Am Acad Dermatol (1987) 0.91
Isoflavone genistein inhibits the initiation and promotion of two-stage skin carcinogenesis in mice. Carcinogenesis (1998) 0.90
Elastin gene deletions in Williams syndrome patients result in altered deposition of elastic fibers in skin and a subclinical dermal phenotype. Pediatr Dermatol (2000) 0.90
Ultraviolet radiation increases tropoelastin accumulation by a post-transcriptional mechanism in dermal fibroblasts. J Invest Dermatol (1995) 0.90
Hypopigmented variant of mycosis fungoides: demography, histopathology, and treatment of seven cases. J Am Acad Dermatol (1995) 0.89
Nerve growth factor receptors on dissociated neurofibroma Schwann-like cells. Cancer Res (1986) 0.89
Effectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgaris. J Am Acad Dermatol (1997) 0.89
Inhibition of ultraviolet B (UVB)-induced c-fos and c-jun expression in vivo by a tyrosine kinase inhibitor genistein. Carcinogenesis (1998) 0.89
Cutaneous mycobacteriosis: occurrence and significance in two patients with the acquired immunodeficiency syndrome. Arch Dermatol (1987) 0.89
Basement membrane proteins, interstitial collagens, and fibronectin in neurofibroma. J Invest Dermatol (1985) 0.88
Differential regulation of P53 and Bcl-2 expression by ultraviolet A and B. J Invest Dermatol (1998) 0.86
Acanthosis Nigricans, insulin action, and hyperandrogenism: clinical, histological, and biochemical findings. J Clin Endocrinol Metab (1991) 0.84
Kaposi's sarcoma and acquired immunodeficiency syndrome. Postmortem findings in twenty-four cases. J Am Acad Dermatol (1987) 0.84
Consensus workshop on the toxic effects of long-term PUVA therapy. Arch Dermatol (1998) 0.84
Tamoxifen reduces endogenous and UV light-induced oxidative damage to DNA, lipid and protein in vitro and in vivo. Carcinogenesis (1998) 0.83
Combination therapy with vitamin D analogues. Br J Dermatol (2001) 0.83
Pseudoxanthoma elasticum and calcinosis cutis. J Am Acad Dermatol (2000) 0.81
Topical corticosteroids in psoriasis: strategies for improving safety. J Eur Acad Dermatol Venereol (2009) 0.81
Peristomal pyoderma gangrenosum. J Am Acad Dermatol (1992) 0.81
The efficacy of metronidazole 1% cream once daily compared with metronidazole 1% cream twice daily and their vehicles in rosacea: a double-blind clinical trial. J Am Acad Dermatol (1998) 0.81
The use of alefacept in the treatment of psoriasis. Skin Therapy Lett (2003) 0.80
Acne therapy: clinical pearls. Semin Cutan Med Surg (2001) 0.80
Multiple hamartoma syndrome. J Am Acad Dermatol (1987) 0.80
Treatment of verrucae vulgaris with alpha 2 interferon. J Infect Dis (1986) 0.80
Pemphigus vulgaris after initiation of psoralen and UVA therapy for psoriasis. J Am Acad Dermatol (1994) 0.80
Photoinduced dermal pigmentation in patients taking tricyclic antidepressants: histology, electron microscopy, and energy dispersive spectroscopy. J Am Acad Dermatol (1999) 0.80
Physician perceptions and experience of current treatment in actinic keratosis. J Eur Acad Dermatol Venereol (2014) 0.80
Association of Pityrosporum orbiculare (Malassezia furfur) with seborrheic dermatitis in patients with acquired immunodeficiency syndrome (AIDS). J Am Acad Dermatol (1989) 0.79
Association between acrochordons and colonic polyps. J Am Acad Dermatol (1986) 0.79
Compatibility of calcipotriene with other topical medications. J Am Acad Dermatol (1998) 0.79
Factors impacting the combination of topical corticosteroid therapies for psoriasis: perspectives from the International Psoriasis Council. J Eur Acad Dermatol Venereol (2011) 0.79
Determination of desmosines in elastin-related skin disorders by isocratic high-performance liquid chromatography. Exp Mol Pathol (1990) 0.79
Alefacept in the treatment of psoriasis in patients for whom conventional therapies are inadequate. Dermatology (2005) 0.79
Cutaneous reactions to vitamin K1 injections. J Am Acad Dermatol (1993) 0.79
PUVA (8-methoxy-psoralen plus ultraviolet A) induces the formation of 8-hydroxy-2'-deoxyguanosine and DNA fragmentation in calf thymus DNA and human epidermoid carcinoma cells. Free Radic Biol Med (1999) 0.79
Presence of type I and VI collagen mRNAs in endothelial cells in cutaneous neurofibromas. Lab Invest (1991) 0.79
Acquired ichthyosis and hyperparathyroidism. J Am Acad Dermatol (1989) 0.79
Tinea versicolor treated with terbinafine 1% solution. Int J Dermatol (1999) 0.78
Cutaneous manifestations of inflammatory bowel disease. J Eur Acad Dermatol Venereol (2000) 0.78
Abnormalities of fibrillin in acquired cutis laxa. J Am Acad Dermatol (1994) 0.78
Elastase digestion of normal and pseudoxanthoma elasticum lesional skin elastins. Exp Mol Pathol (1991) 0.78
Interactions between tazarotene and ultraviolet light. J Am Acad Dermatol (1999) 0.77
The cost of psoriasis treatment. J Eur Acad Dermatol Venereol (2001) 0.77
Topical calcipotriene in combination with UVB phototherapy for psoriasis. Int J Dermatol (1997) 0.77
A double-blind, vehicle-controlled study of clobetasol propionate 0.05% (Temovate) scalp application in the treatment of moderate to severe scalp psoriasis. J Am Acad Dermatol (1991) 0.77
Psoriasis. Drugs Today (Barc) (1998) 0.76
Psoriasis and Crohn's disease. Mt Sinai J Med (1999) 0.76
In vitro compatibility of tazarotene with other topical treatments of psoriasis. J Am Acad Dermatol (2000) 0.76
Retrospective study of the efficacy of narrowband UVB and acitretin. J Dermatolog Treat (2003) 0.76
From the literature: intralesional 5-FU in the treatment of hypertrophic scars and keloids: clinical experience. J Am Acad Dermatol (2000) 0.76
Cost-effectiveness of methotrexate and Goeckerman therapy: a flawed analysis. Arch Dermatol (1999) 0.75
Improving the safety profile of long-term PUVA therapy. J Am Acad Dermatol (1999) 0.75
Retrospective analysis of the treatment of psoriasis of the palms and soles. J Dermatolog Treat (2003) 0.75
Erythema nodosum. Mt Sinai J Med (1999) 0.75
Addition of short-contact anthralin therapy to an ultraviolet B phototherapy regimen: assessment of efficacy. J Am Acad Dermatol (1985) 0.75
The penetration of 0.005% fluticasone propionate ointment in eyelid skin. J Am Acad Dermatol (2001) 0.75
Clinical pearl: vitamin E (alpha-tocopherol), 800 IU daily, may reduce retinoid toxicity. J Am Acad Dermatol (1999) 0.75
Reactive perforating collagenosis. Mt Sinai J Med (1998) 0.75
Cimetidine therapy for plantar warts. J Am Podiatr Med Assoc (1995) 0.75
Generalized morphea. Mt Sinai J Med (1998) 0.75
Case 2-1995. From the weekly grand rounds of the Department of Dermatology at the Mount Sinai Hospital. Mt Sinai J Med (1995) 0.75
Genital lentigines in a 6-year-old boy with a family history of Cowden's disease: clinical and genetic evidence of the linkage between Bannayan-Riley-Ruvacalba syndrome and Cowden's disease. J Cutan Med Surg (2001) 0.75
Pseudoxanthoma elasticum and pregnancy. Cutis (1996) 0.75
Topical antipsoriatics. Skin Therapy Lett (2000) 0.75
Comparison of urinary 8-hydroxy-2'-deoxyguanosine in patients treated with topical corticosteroids, UV-B, and psoralen UV-A therapies. Arch Dermatol (2000) 0.75
Transition from methotrexate and cyclosporine to other therapies including retinoids, ultraviolet light and biologic agents in the management of patients with psoriasis. J Dermatolog Treat (2003) 0.75
Lyme disease. Mt Sinai J Med (1997) 0.75
Calcipotriene ointment applied once a day for psoriasis: a double-blind, multicenter, placebo-controlled study. Arch Dermatol (1996) 0.75
In vivo expression of the insulin-like growth factor-I (IGF-I) receptor in congenital pigmented nevi. J Cutan Pathol (1996) 0.75
The case for micrographically controlled skin surgery. J Am Acad Dermatol (2000) 0.75